{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:14:34Z","timestamp":1777936474843,"version":"3.51.4"},"reference-count":14,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2011,12,19]],"date-time":"2011-12-19T00:00:00Z","timestamp":1324252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Mult Scler"],"published-print":{"date-parts":[[2012,6]]},"abstract":"<jats:p>Natalizumab is frequently used as a treatment for multiple sclerosis (MS). The occurrence of progressive multifocal leukoencephalopathy (PML) in natalizumab-treated patients indicates that its prominent beneficial effects need to be balanced against the risks. Also, cessation of the drug seems to be associated with recurrence of disease activity. Both the moment of rebound disease activity and the outcome of PML are related to clearance of the drug. Specific features of this IgG4 antibody (i.e. half-antibody exchange) may result in underestimated drug levels. Here, we demonstrate natalizumab levels in 10 patients with relapsing MS, using a recently developed sensitive assay. Remarkably, natalizumab was detectable up to 200 days after cessation of therapy.<\/jats:p>","DOI":"10.1177\/1352458511431073","type":"journal-article","created":{"date-parts":[[2011,12,20]],"date-time":"2011-12-20T00:08:39Z","timestamp":1324339719000},"page":"899-901","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":36,"title":["Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped"],"prefix":"10.1177","volume":"18","author":[{"given":"Theo","family":"Rispens","sequence":"first","affiliation":[{"name":"Sanquin Research, Amsterdam, The Netherlands"},{"name":"Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anke","family":"Vennegoor","sequence":"additional","affiliation":[{"name":"VU University Medical Centre, Department of Neurology (MS Centre Amsterdam), Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gert Jan","family":"Wolbink","sequence":"additional","affiliation":[{"name":"Sanquin Research, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris H","family":"Polman","sequence":"additional","affiliation":[{"name":"VU University Medical Centre, Department of Neurology (MS Centre Amsterdam), Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joep","family":"Killestein","sequence":"additional","affiliation":[{"name":"VU University Medical Centre, Department of Neurology (MS Centre Amsterdam), Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2011,12,19]]},"reference":[{"key":"bibr1-1352458511431073","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044397"},{"key":"bibr2-1352458511431073","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70028-4"},{"key":"bibr3-1352458511431073","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2010.161"},{"key":"bibr4-1352458511431073","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22074"},{"key":"bibr5-1352458511431073","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22163"},{"key":"bibr6-1352458511431073","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000341766.59028.9d"},{"key":"bibr7-1352458511431073","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.5.1072"},{"key":"bibr8-1352458511431073","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.26260"},{"key":"bibr9-1352458511431073","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2011.01.001"},{"key":"bibr10-1352458511431073","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1553"},{"key":"bibr11-1352458511431073","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2011.01.006"},{"key":"bibr12-1352458511431073","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.4049\/jimmunol.155.10.5057","volume":"155","author":"Zack DJ","year":"1995","journal-title":"J Immunol"},{"key":"bibr13-1352458511431073","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0804338"},{"key":"bibr14-1352458511431073","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31820b7644"}],"container-title":["Multiple Sclerosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1352458511431073","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1352458511431073","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1352458511431073","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:33:01Z","timestamp":1777692781000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1352458511431073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,19]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["10.1177\/1352458511431073"],"URL":"https:\/\/doi.org\/10.1177\/1352458511431073","relation":{},"ISSN":["1352-4585","1477-0970"],"issn-type":[{"value":"1352-4585","type":"print"},{"value":"1477-0970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,19]]}}}